Business Description
InflaRx NV
ISIN : NL0012661870
Description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 64.44 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.61 | |||||
| Beneish M-Score | 3.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 17.6 | |||||
| 3-Year EPS without NRI Growth Rate | 18.4 | |||||
| 3-Year FCF Growth Rate | 23 | |||||
| 3-Year Book Growth Rate | -17.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 495.94 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.08 | |||||
| 9-Day RSI | 42.41 | |||||
| 14-Day RSI | 48.62 | |||||
| 6-1 Month Momentum % | 37.92 | |||||
| 12-1 Month Momentum % | 45.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.31 | |||||
| Quick Ratio | 4.61 | |||||
| Cash Ratio | 4.17 | |||||
| Days Inventory | 4137.31 | |||||
| Days Sales Outstanding | 106.54 | |||||
| Days Payable | 4365.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.8 | |||||
| Shareholder Yield % | 0.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -351.35 | |||||
| Operating Margin % | -33355.14 | |||||
| Net Margin % | -33589.19 | |||||
| FCF Margin % | -28333.93 | |||||
| ROE % | -61.93 | |||||
| ROA % | -54.1 | |||||
| ROIC % | -458.61 | |||||
| ROC (Joel Greenblatt) % | -1694.56 | |||||
| ROCE % | -61.42 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 836.67 | |||||
| PB Ratio | 2.04 | |||||
| Price-to-Tangible-Book | 2.04 | |||||
| EV-to-EBIT | -1.41 | |||||
| EV-to-Forward-EBIT | -8.19 | |||||
| EV-to-EBITDA | -1.43 | |||||
| EV-to-Forward-EBITDA | -8.19 | |||||
| EV-to-Revenue | 474.41 | |||||
| EV-to-Forward-Revenue | 87.06 | |||||
| EV-to-FCF | -1.69 | |||||
| Price-to-Net-Current-Asset-Value | 2.25 | |||||
| Price-to-Net-Cash | 3.06 | |||||
| Earnings Yield (Greenblatt) % | -70.92 | |||||
| FCF Yield % | -35.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
InflaRx NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.168 | ||
| EPS (TTM) (€) | -0.99 | ||
| Beta | 0.88 | ||
| Volatility % | 78.76 | ||
| 14-Day RSI | 48.62 | ||
| 14-Day ATR (€) | 0.122008 | ||
| 20-Day SMA (€) | 2.1959 | ||
| 12-1 Month Momentum % | 45.55 | ||
| 52-Week Range (€) | 1.073 - 2.502 | ||
| Shares Outstanding (Mil) | 58.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
InflaRx NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
InflaRx NV Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
InflaRx NV Frequently Asked Questions
What is InflaRx NV(STU:IF0)'s stock price today?
The current price of STU:IF0 is €2.02. The 52 week high of STU:IF0 is €2.50 and 52 week low is €1.07.
When is next earnings date of InflaRx NV(STU:IF0)?
The next earnings date of InflaRx NV(STU:IF0) is 2025-03-21 Est..
Does InflaRx NV(STU:IF0) pay dividends? If so, how much?
InflaRx NV(STU:IF0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers